FDA-approved strategies for managing severe COVID-19 include the inhibition of IL-664 or downstream (through JAK1/265) signaling, and modern cancer therapies frequently leverage checkpoint inhibitors to reinvigorate adaptive immunity in patients with cancer, raising the prospect of interventions that could reduce the risk of respiratory virus infection-induced metastatic cancer progression. The gene discussed is JAK1; the disease is COVID-19.